Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO™ (Nitroglycerin) Sublingual Powder
Available in Single Dose Packets, GONITRO™ is Approved For Acute Relief of an Angina Pectoris Attack Due to Coronary Artery Disease
JACKSONVILLE, Fla. (August 30, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that DDB Health, an Omnicom Health Group company, as its agency of record for GONITRO™. Omnicom is the largest healthcare marketing and communications group in the world.
Additionally, Espero Pharmaceuticals has also partnered with Alamo Pharma Services, a leading pharmaceutical commercial solutions provider to launch a stand-alone cardiovascular sales team dedicated to the promotion of GONITRO™. Alamo will assist with the recruiting, hiring, and ongoing operational support for the Espero professional sales team.
“We are pleased to have DDB Health, the best creative team in cardiovascular marketing, to help us launch GONITRO™,” said Quang Pham, Chairman and CEO of Espero Pharmaceuticals. “With Alamo Pharma Services, we are able to recruit and attract outstanding sales candidates and have first-class operational support.”
“We are extremely excited at the opportunity to creatively and strategically partner with Espero Pharmaceuticals to introduce this innovative new option for patients who live with angina,” commented Patricia Malone, Senior Vice President and Creative Director, DDB Health.
“It is very exciting to have been chosen by Espero Pharmaceuticals,” added Peter Marchesini, Chief Operating Officer of Alamo Pharma Services. “This partnership will allow Alamo to provide our customized services, enabling Espero the opportunity to concentrate on revenue generating activities.”
GONITRO™ is the first and only short-acting nitrate in a stabilized crystal granule form available in a single dose packet. Each individual packet of GONITRO™ contains 400 mcg of nitroglycerin. The clinical data indicate that the sublingual absorption of nitroglycerin is higher following the administration of GONITRO™ compared to Nitrolingual® Pumpspray (nitroglycerin lingual spray) which was launched in 1997 and is currently marketed by Espero in the United States. GONITRO™ will be commercially available in September 2016.
Please see Full Prescribing information available at www.gonitrorx.com.
For more information regarding DDB Health, visit www.ddbhealth.com.
For more information regarding Alamo Pharma Services, visit www.alamopharmaservices.com.
About Espero Pharmaceuticals
Espero Pharmaceuticals, Inc., www.esperopharma.com, headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients.